Exact Sciences will acquire Genomic Health, a provider of genomic-based diagnostic tests that help optimize cancer care, in a cash and stock transaction valued at $2.8 billion, the company announced today.

According to a release, the combined companies will be a leader in global cancer diagnostics by offering two fast-growing brands. Exact Science’s Cologuard helps detect colorectal cancer, while Genomic Health’s Oncotype DX informs treatment decisions in colorectal, breast and prostate cancer.

“Uniting the best minds and molecular diagnostics capabilities will advance the fight against cancer,” Exact Sciences CEO Kevin Conroy said in a statement. “Combining industry pioneers Exact Sciences and Genomic Health is a pivotal step toward building the leading cancer diagnostics company in the world.”

The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to be completed by the end of 2019. The combined companies will have an estimated $1.6 billion in revenue and approximately $1.2 billion in gross profit in 2020.